Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 3Adenocarcinoma Of Esophagus 2Solid Tumor 1Sarcoma, Clear Cell 1Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Bevacizumab 14Cisplatin 12Surveys and Questionnaires 11Gemcitabine 9Drug Therapy 9Standard of Care 8Nivolumab 7Cetuximab 7pembrolizumab 6S 1 (combination) 6Cyclophosphamide 6atezolizumab 5Specimen Handling 5Endoscopic Mucosal Resection 5Educational Status 5Docetaxel 5Blood Specimen Collection 5fludarabine 4aldesleukin 4Radiotherapy 4Radiosurgery 4Pemetrexed 4IFL protocol 4Folfox protocol 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Neoplasms × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡